Table 1 Predicted serotype-specific protective antibody concentration for the PCV7 serotypes in PCV13.

From: Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data

Serotype

Protective antibody concentration Median (95% CI), µg/mL

United Kingdom

Australia

Germany

4

0.40 (0.18–1.29)

0.75 (0.44–1.52)

2.96 (0.46-∞a)

6B

0.08 (0.02–2.28)

1.38 (0.38-∞a)

0.08 (0.02–0.75)

9 V

0.51 (0.17-∞a)

0.93 (0.55–1.90)

0.87 (0.27-∞a)

14

0.63 (0.22–1.58)

1.92 (0.57-∞a)

0.63 (0.22–2.82)

18 C

0.15 (0.05–0.43)

0.84 (0.38–3.69)

1.13 (0.37-∞a)

19 F

1.27 (0.52–5.19)

6.08 (1.05-∞a)

1.50 (0.47-∞a)

23 F

0.20 (0.06–1.87)

0.64 (0.20-∞a)

0.34 (0.08-∞a)

  1. CI confidence interval.
  2. aThe infinite estimates correspond to serotype-specific effectiveness inputs with lower bounds that are negative, or very close to being negative. In cases where the lower bound of the VE is negative, there would be simulations that would sample and input these negative effectiveness values into the calculation. When this happens a Cp cannot be estimated, and an infinite value is produced.
Back to article page